Generally, a common multipotent stem cell is the origin of various blood cells, including erythrocytes, lymphocytes, granulocytes, and macrophages. Particularly in adult, haemopoietic stem cells are mainly seen in bone marrow, and they depend on contact-mediated signals from the marrow stromal (connective-tissue) cells to maintain their stem-cell character. The stem cells normally divide infrequently to produce more stem cells (selfrenewal) and various committed progenitor cells (transit amplifying cells), each able to give rise to only one or a few types of blood cells. Blood transfusions hold an indispensable part in the modern healthcare system. Up to date, the blood supply is largely dependent on donations and further its supply is limited due to clinical guide, So it is required to produce blood in some other means. In the meantime, the concept of in vitro/ex vivo production of blood cells has been emerging and many attempts have been focused on manufacturing mature erythrocytes, In this review, a focus is made on (a) cell fate reprogramming using haematopoietic transcription factors (TFs) (b) genetic modifications for immortalisation of blood-derived erythroblasts. The limitations and future perspective to overcome the limitations are discussed.